Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 255-264

  Zhang, Kun ^a,b   Zhou, Yong Qing ^a   Yao, Hang Ping ^a   Wang, Ming Hai ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Aberrant splicing; EMT; Epithelial cells; Macrophage stimulating protein receptor; Receptor tyrosine kinase

Indexed keywords

AMINO ACID; IMMUNOGLOBULIN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; OLIGOMER; PLEXIN; PROTEIN TYROSINE KINASE; RON 165 ELLP PROTEIN; RON 165 PROTEIN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

AMINO ACID SEQUENCE; ARTICLE; BIOCHEMISTRY; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CELL ACTIVITY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOPLASM; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; EPITHELIUM CELL; EXON; GENE CONTROL; GENE DELETION; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CELL; MESENCHYME; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN VARIANT; RNA SPLICING; RNA TRANSCRIPTION; RNA TRANSLATION; SPINDLE CELL CARCINOMA;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; CELL MOVEMENT; DOGS; EPITHELIAL CELLS; EXONS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 74549155914     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000496     Document Type: Article

References (29)

1. Ménard S, Pupa SM, Campiglio PM and Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene 22: 6570-6578, 2003.
2. Benvenuti S and Comoglio PM: The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213: 316-325, 2007.
3. Holmes K, Roberts OL, Thomas AM and Cross ML: Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 19: 2003-2012, 2007.
4. Comoglio PM and Trusolino L: Invasive growth: from development to metastasis. J Clin Invest 109: 857-862, 2002.
5. Robert NL and Favret AM: HER2-positive advanced breast cancer. Hematol Oncol Clin North Am 21: 293-302, 2007.
6. Lengyel E, Sawada K and Salgia R: Tyrosine kinase mutations in human cancer. Curr Mol Med 7: 77-84, 2007.
7. Ronsin C, Muscatelli F, Mattei MG and Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8: 1195-1202, 1993.
8. Maggiora P, Marchio S, Stella, MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P and Comoglio PM: Overexpression of the RON gene in human breast carcinoma. Oncogene 16: 2927-2933, 1998.
9. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH and Waltz SE: Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 66: 11967-11974, 2006.
10. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH and Bishop JM: The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 104: 7570-7575, 2007.
11. Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257: 157-164, 2007.
12. Wang MH, Lee W, Luo YL, Weis MT and Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol 213: 402-411, 2007.
13. Lee WY, Chen HH, Chow NH, Su WC, Lin PW and Guo HR: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 11: 2222-2228, 2005.
14. Ghigna G, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S and Biamonti G: Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 20: 881-890, 2005.
15. Bardella C, Costa B, Maggiora P, Patane S, Olivero M, Ranzani GN, De Bortoli M, Comoglio PM and Di Renzo MF: Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res 64: 5154-5161, 2004.
16. Collesi C, Santoro MM, Gaudino G and Comoglio PM: A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 16: 5518-5526, 2006.
17. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ and Lerman MI: Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 29: 147-156, 2000.
18. Wang D, Shen Q, Chen YQ and Wang MH: Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 23: 1668-1680, 2004.
19. Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W and Wang MH: Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 5: 1179-1186, 2006.
20. Zhou YQ, He C, Chen YQ, Wang D and Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 22: 186-197, 2003.
21. Zhang K, Yao HP and Wang MH: Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility. Carcinogenesis 29: 552-559, 2008.
22. Wang D, Shen Q, Xu XM, Chen YQ and Wang MH: Activation of the RON receptor tyrosine kinase attenuates transforming growth factor-beta1-induced apoptotic death and promotes phenotypic changes in mouse intestinal epithelial cells. Carcinogenesis 26: 27-36, 2005.
23. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005.
24. Van Itallie CM and Anderson JM: Claudins and epithelial paracellular transport. Annu Rev Physiol 68: 403-429, 2006.
25. Flores-Benitez D, Ruiz-Cabrera A, Flores-Maldonado C, Shoshani L, Cereijido M and Contreras RG: Control of tight junctional sealing: role of epidermal growth factor. Am J Physiol Renal Physiol 292: F828-F836, 2007.
26. Christiansen JJ and Rajasekaran AK: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66: 8319-8326, 2006.
27. Okino T, Egami H, Ohmachi H, Takai E, Tamori Y, Nakagawa K, Nakano S, Akagi J, Sakamoto O, Suda T and Ogawa M: Presence of RON receptor tyrosine kinase and its splicing variant in malignant and non-malignant human colonic mucosa. Int J Oncol 15: 709-714, 1999.
28. Xu XM, Zhou YQ and Wang MH: Mechanisms of cytoplasmic β-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem 280: 25087-25094, 2005.
29. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D and Krainer AR: The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14: 185-193, 2007.